Full Text Journal Articles by
Author Ray Page

Advertisement

Find full text journal articles






A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.

David R Spigel, Dianna L Shipley, David M Waterhouse, Suzanne F Jones, Patrick J Ward, Kent C Shih, Brian Hemphill, Michael McCleod, Robert C Whorf, Ray D Page, Joseph Stilwill, Tarek Mekhail, Cindy Jacobs, Howard A Burris, John D Hainsworth,

BACKGROUND:This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). METHODS:Patients were randomized 1:1 to Arm A (carboplatin/pemetrexed plus apatorsen) ... Read more >>

Oncologist (The oncologist)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Opioids and Cancer Pain: Patients' Needs and Access Challenges.

Ray Page, Elizabeth Blanchard,

J Oncol Pract (Journal of oncology practice)
[2019, 15(5):229-231]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman, Vassiliki A Papadimitrakopoulou,

PURPOSE:Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended by professional guidelines. We aimed to demonstrate noninferiority of comprehensive cell-free DNA (cfDNA) relative to physician discretion standard-of-care (SOC) tissue ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(15):4691-4700]

Cited: 3 times

View full text PDF listing >>



Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.

Joshua Kraut, Kathi Mooney, John W Sweetenham, Ray D Page, Kerin Adelson, Vineeta Agarwala, Kristen L Fessele, H James Hamrick, Irene Kaganman, James Martineau, Amy P Abernethy, Neal J Meropol,

J Oncol Pract (Journal of oncology practice)
[2019, 15(4):220-223]

Cited: 0 times

View full text PDF listing >>



Reducing Cancer Costs Through Symptom Management and Triage Pathways.

Ronald Barkley, Mah-Jabeen Soobader, Jun Wang, Sibel Blau, Ray D Page,

PURPOSE:Value-based care infers care that is high quality at a comparatively low total cost. A key strategy for value-based oncology care is to avoid unnecessary emergency room (ER) visits and associated hospitalizations of patients receiving treatment for cancer. Early experience with this strategy showed that symptom management in patients with ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2019, 15(2):e91-e97]

Cited: 0 times

View full text PDF listing >>



Safe Handling of Hazardous Drugs: ASCO Standards.

Paul Celano, Christopher A Fausel, Erin B Kennedy, Tim M Miller, Thomas K Oliver, Ray Page, Jeffery C Ward, Robin T Zon,

PURPOSE:To provide 2019 ASCO standards on the safe handling of hazardous drugs. METHODS:An Expert Panel was formed, and a systematic review of the literature on closed system transfer devices was performed to May 2017 using PubMed. The Cochrane Database of Systematic Reviews, PubMed, and Google Scholar were used to search ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(7):598-609]

Cited: 0 times

View full text PDF listing >>



Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit, Byoung C Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E Gray, Luis Paz-Ares, Javier de Castro Carpeño, Corinne Faivre-Finn, Martin Reck, Johan Vansteenkiste, David R Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A Dennis, Mustafa Özgüroğlu, ,

BACKGROUND:An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2018, 379(24):2342-2350]

Cited: 75 times

View full text PDF listing >>



Impact on Oncology Practices of Including Drug Costs in Bundled Payments.

Jeffery C Ward, Laura A Levit, Ray D Page, John E Hennessy, John V Cox, Deborah Y Kamin, Suanna S Bruinooge, Ya-Chen Tina Shih, Blase N Polite,

INTRODUCTION:This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. METHODS:An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non-small-cell lung cancer. First quarter 2016 Medicare reimbursement rates were used to calculate the average fee-for-service (FFS) reimbursement for these vignettes. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(5):e259-e268]

Cited: 3 times

View full text PDF listing >>



Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors.

Bobby Daly, Peter B Bach, Ray D Page,

JAMA Oncol (JAMA oncology)
[2018, 4(2):255-257]

Cited: 1 time

View full text PDF listing >>



Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid, Paolo Bidoli, Paul Wheatley-Price, Keunchil Park, Ross A Soo, Yifan Huang, Catherine Wadsworth, Phillip A Dennis, Naiyer A Rizvi, ,

BACKGROUND:Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2018, 19(4):521-536]

Cited: 50 times

View full text PDF listing >>



Oncology Clinical Pathways: Charting the Landscape of Pathway Providers.

Bobby Daly, Robin T Zon, Ray D Page, Stephen B Edge, Gary H Lyman, Sybil R Green, Dana S Wollins, Linda D Bosserman,

J Oncol Pract (Journal of oncology practice)
[2018, 14(3):e194-e200]

Cited: 2 times

View full text PDF listing >>



When Investment Meets Return.

Robin Zon, Ray Page,

J Oncol Pract (Journal of oncology practice)
[2018, 14(3):147-148]

Cited: 0 times

View full text PDF listing >>



Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.

Casey Mason, Peter G Ellis, Kathy Lokay, Amanda Barry, Natalie Dickson, Ray Page, Blase Polite, Ravi Salgia, Michael Savin, Corey Shamah, Mark A Socinski,

Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non-small cell lung cancer (NSCLC), there is evidence that testing has not been widely embraced in the clinical setting. This study uses clinical pathways to understand biomarker testing patterns and ... Read more >>

J Clin Pathw (Journal of clinical pathways : the foundation of value-based care)
[2018, 4(1):49-54]

Cited: 0 times

View full text PDF listing >>



Measuring Quality Is Complicated.

Debra Patt, Ray Page,

J Oncol Pract (Journal of oncology practice)
[2018, 14(1):1-2]

Cited: 0 times

View full text PDF listing >>



nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Michael Thomas, David R Spigel, Robert M Jotte, Michael McCleod, Mark A Socinski, Ray D Page, Laurent Gressot, Jeanna Knoble, Oscar Juan, Daniel Morgensztern, Dolores Isla, Edward S Kim, Howard West, Amy Ko, Teng Jin Ong, Nataliya Trunova, Cesare Gridelli,

Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy.Patients ... Read more >>

Lung Cancer (Auckl) (Lung Cancer (Auckland, N.Z.))
[2017, 8:207-216]

Cited: 2 times

View full text PDF listing >>



Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit, Byoung C Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E Gray, Luis Paz-Ares, Javier de Castro Carpeño, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A Dennis, Mustafa Özgüroğlu, ,

BACKGROUND:Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2017, 377(20):1919-1929]

Cited: 399 times

View full text PDF listing >>



The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer.

Ray D Page, A Christine Argento, David B Nash, Alexandria Skoufalos, Eric S Schaefer,

The Oncology Care Model (OCM) is a payment model from the Centers for Medicare and Medicaid Services designed to reduce costs and improve quality in cancer care. Key components of quality for the OCM originate from the 13-component cancer care plan. We surveyed the literature to understand the value of ... Read more >>

Manag Care (Managed care (Langhorne, Pa.))
[2017, 26(9):37-47]

Cited: 0 times

View full text PDF listing >>



Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.

Wallace L Akerley, Alix M Arnaud, Bibas Reddy, Ray D Page,

The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying patients into two categories. Patients classified as VSGood have a favorable prognosis and significant clinical response to EGFR tyrosine kinase inhibitors (TKIs). Patients classified as ... Read more >>

Curr Med Res Opin (Current medical research and opinion)
[2017, 33(6):1091-1097]

Cited: 3 times

View full text PDF listing >>



American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology.

Robin T Zon, Stephen B Edge, Ray D Page, James N Frame, Gary H Lyman, James L Omel, Dana S Wollins, Sybil R Green, Linda D Bosserman,

J Oncol Pract (Journal of oncology practice)
[2017, 13(3):207-210]

Cited: 6 times

View full text PDF listing >>



PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Hui Yu, Cory Batenchuk, Andrzej Badzio, Theresa A Boyle, Piotr Czapiewski, Daniel C Chan, Xian Lu, Dexiang Gao, Kim Ellison, Ashley A Kowalewski, Christopher J Rivard, Rafal Dziadziuszko, Caicun Zhou, Maen Hussein, Donald Richards, Sharon Wilks, Marc Monte, William Edenfield, Jerome Goldschmidt, Ray Page, Brian Ulrich, David Waterhouse, Sandra Close, Jacek Jassem, Kimary Kulig, Fred R Hirsch,

Therapeutic antibodies to immune checkpoints show promising results. Programmed death-ligand 1 (PD-L1), an immune checkpoint ligand, blocks the cancer immunity cycle by binding the PD-L1 receptor (programmed death 1). We investigated PD-L1 protein expression and messenger RNA (mRNA) levels in SCLC.PD-L1 protein expression and mRNA levels were determined by immunohistochemistry ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2017, 12(1):110-120]

Cited: 23 times

View full text PDF listing >>



American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology.

Robin T Zon, James N Frame, Michael N Neuss, Ray D Page, Dana S Wollins, Steven Stranne, Linda D Bosserman,

The use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders. These include the process being used ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2016, 12(3):261-266]

Cited: 22 times

View full text PDF listing >>



A Pathway Through the Bundle Jungle.

Blase Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2016, 12(6):504-509]

Cited: 11 times

View full text PDF listing >>



Refining the Standard of Care: How Oncology Treatment Pathways Can Make a Difference.

Ray D Page,

J Oncol Pract (Journal of oncology practice)
[2016, 12(2):143-144]

Cited: 1 time

View full text PDF listing >>



Oncology Pathways-Preventing a Good Idea From Going Bad.

Blase N Polite, Ray D Page, Chadi Nabhan,

JAMA Oncol (JAMA oncology)
[2016, 2(3):297-298]

Cited: 4 times

View full text PDF listing >>



Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice.

Donald Richards, Si G Li, Thomas Anderson, Marc Monte, Brian Ulrich, David A Smith, Mahesh Seetharam, Paul Kaywin, Ray Page, Kimary Kulig, Cory Batenchuk, Maen Hussein,

J Immunother Cancer (Journal for immunotherapy of cancer)
[2015, 3(Suppl 2):P170-P170]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
2.1473 s